Chronic Lymphocytic Leukemia
Chronic Lymphocytic Leukemia
The latest news, research, and perspectives in chronic lymphocytic leukemia (CLL). The most common leukemia subtype among adults, CLL occurs when an acquired mutation causes bone marrow to produce abnormal lymphocytes. As these leukemic cells proliferate, the disorder is associated with lymphadenopathy, splenomegaly, and cytopenias.
Advertisement
Cailin ConnerChronic Lymphocytic Leukemia | September 22, 2023
The primary endpoints of the phase III ELEVATE-RR study were PFS, AEs, and events of clinical interest.
Read More
Cailin ConnerChronic Lymphocytic Leukemia | September 22, 2023
Reseserchers with the German CLL Study Group conducted a prospective analysis of karyotype complexity in patients with CLL.
Cailin ConnerChronic Lymphocytic Leukemia | September 22, 2023
Patients with mutated IGHV had a median PFS of 14.6 years compared with 4.2 years in patients with unmutated IGHV.
Cecilia BrownChronic Lymphocytic Leukemia | September 20, 2023
Dr. Coombs discusses her journey into oncology, what it’s like to broach the lymphoid and myeloid worlds, and a unique ...
Othman Al-Sawaf, MDChronic Lymphocytic Leukemia | September 20, 2023
Othman Al-Sawaf, MD, and Nicole Lamanna, MD, debate approaches in this Point | Counterpoint.
Mary Ann Anderson, MBBS, PhDChronic Lymphocytic Leukemia | September 19, 2023
Mary Ann Anderson, MBBS, PhD, of the Peter MacCallum Cancer Centre, discusses the importance of World CLL Day.
Advertisement
Alessandra Ferrajoli, MDMeeting News | September 14, 2023
Alessandra Ferrajoli, MD, discusses her presentation on the topic during the Eleventh Annual Meeting of SOHO.
Mary Ann Anderson, MBBS, PhDMeeting News | September 13, 2023
Dr. Anderson spoke about her plenary session on the topic at the Eleventh Annual Meeting of SOHO.
Cecilia BrownChronic Lymphocytic Leukemia | September 11, 2023
All patients included in the study required treatment and had not previously received psychiatric treatment.
Cecilia BrownMeeting News | September 11, 2023
The study included patients with relapsed or refractory B-cell malignancies who were in the phase I/II BRUIN trial.
Cecilia BrownChronic Lymphocytic Leukemia | September 11, 2023
The researchers investigated if iso-cel in patients with relapsed or refractory CLL is a cost-efficient option.
Cailin ConnerMeeting News | September 10, 2023
Noteworthy regional disparities were noticed in treatment strategies.
Cailin ConnerChronic Lymphocytic Leukemia | September 10, 2023
Investigators from the Mayo Clinic identified 145 patients with CLL who were treated between 2014-2021.
Cecilia BrownChronic Lymphocytic Leukemia | September 7, 2023
Dr. Brown shares what CLL news and session she's watching at the Eleventh Annual Meeting of SOHO.
Cecilia BrownChronic Lymphocytic Leukemia | August 30, 2023
Ibrutinib has a monthly sticker price of $17,000 and was taken by 20,000 people who were beneficiaries of Medicare.
Chadi Nabhan, MD, MBA, FACPChronic Lymphocytic Leukemia | August 24, 2023
Dr. Shadman rounds up the latest news on CLL from the summer conferences in this episode of The HemOnc Pulse.
Patrick DalyChronic Lymphocytic Leukemia | August 7, 2023
SF3B1 mutation in CLL cells leads to RNA dysfunction and chromosomal instability and potentially drives disease progression.
Patrick DalyChronic Lymphocytic Leukemia | August 7, 2023
Pirtobrutinib effectively recovered BTK inhibition in patients with CLL or SLL who previously failed a BTK inhibitor.
Patrick DalyChronic Lymphocytic Leukemia | August 7, 2023
Venetoclax plus obinutuzumab with or without ibrutinib improved MRD and PFS outcomes compared with chemoimmunotherapy.
Chadi Nabhan, MD, MBA, FACPChronic Lymphocytic Leukemia | July 27, 2023
Nitin Jain, MD, discusses the data on venetoclax combinations in CLL and key frontline treatment considerations.
Advertisement
Advertisement
Editorial Board